Pharmaceutical

Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced longer-term data from its ongoing dose-ranging Phase 1b trial of VY-AADC in advanced Parkinson’s disease. As quoted in the press release: “We continue to be pleased with the duration and magnitude of effect of VY-AADC on …

Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced longer-term data from its ongoing dose-ranging Phase 1b trial of VY-AADC in advanced Parkinson’s disease.

As quoted in the press release:

“We continue to be pleased with the duration and magnitude of effect of VY-AADC on multiple measures of patients’ motor function and quality of life, which is consistent with the mechanism of action of VY-AADC suggesting a greater capacity for patients to make more dopamine and improve their motor function with less need for oral levodopa,” said Bernard Ravina, M.D., M.S., chief medical officer of Voyager Therapeutics.

Click here to read the full press release.

MARKETS

Markets
TSX18937.71+342.09
TSXV606.34+9.14
DOW31827.05+754.44
S&P 5003936.69+105.84
NASD11713.15+353.10
ASX6649.60-37.50

COMMODITIES

Commodities
Gold1711.29+1.27
Silver18.76-0.01
Copper3.30+0.01
Palladium1894.50+16.50
Platinum881.50+5.50
Oil103.51-0.71
Heating Oil3.59+0.02
Natural Gas7.24-0.03

DOWNLOAD FREE REPORTS

×